Understanding how the immune system affects lung cancer treatment responses
Role of Adaptive Immunity in Lung Cancer Response to Oncogene-targeted Therapeutics
This study is looking at how the immune system affects the way lung cancer patients respond to certain targeted treatments, hoping to find out why some people do better than others, so they can create more personalized and effective treatment options for everyone.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | VA Eastern Colorado Health Care System NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-10919324 on NIH RePORTER |
What this research studies
This research investigates the role of adaptive immunity in how lung cancer patients respond to targeted therapies that inhibit specific oncogenes. By analyzing blood and biopsy samples from patients with lung adenocarcinomas driven by certain genetic mutations, the study aims to uncover why some patients experience better outcomes than others when treated with targeted therapies. The researchers will explore the interactions between immune cells and cancer cells to identify potential new treatment strategies that could enhance the effectiveness of existing therapies. This work could lead to personalized treatment approaches based on individual immune responses.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with lung adenocarcinoma driven by specific oncogenic mutations such as EGFR or ALK.
Not a fit: Patients with lung cancer types not driven by the targeted oncogenes being studied may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for lung cancer patients, enhancing their response to therapies and potentially increasing survival rates.
How similar studies have performed: Previous studies have shown that understanding the immune response can significantly impact treatment outcomes in cancer, suggesting that this approach may yield valuable insights.
Where this research is happening
Aurora, UNITED STATES
- VA Eastern Colorado Health Care System — Aurora, United States (Active)
Researchers
- Principal investigator: Heasley, Lynn E — VA Eastern Colorado Health Care System
- Study coordinator: Heasley, Lynn E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.